Thomas Gad | Founder, Chairman, President & Head, Business Development & Strategy |
Claus Moller | Chief Executive Officer |
Bo Kruse | Executive Vice President & Chief Financial Office |
Alec Stranahan | Bank of America Merrill Lynch |
Etzer Darout | Guggenheim Securities, LLC |
Robert Burns | H.C. Wainwright & Co., LLC |
David Lebowitz | Morgan Stanley |
Peter Lawson | Barclays Investment Bank |
Good morning, and welcome to the Y-mAbs Therapeutics, Inc.
Second Quarter 2020 Earnings Conference Call. Today's conference is being recorded.
Let me quickly remind you that the following discussion contains certain statements that are considered forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Because forward-looking statements involve risks and uncertainties, they are not guarantees of future performance, and actual results may differ materially from those expressed or implied by these forward-looking statements due to a variety of factors, including those factors discussed in the company's annual report on Form 10-K for the fiscal year ended December 31, 2019, as well as with the SEC on March 12, 2020, and in the company's sequentially filed SEC reports.